Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
Returns on capital
Rani Therapeutics Holdings, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-89.9%
avg -274.2%
ROIC
-80.6%
avg -89.1%
ROA
-50.6%
avg -51.8%
Analysis
ROA is currently the strongest return metric at -50.6% versus its period average of -51.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Nicholas Maestas | Chief Financial Officer | USD 791.41K | 46 | 2.00M | 3.06% |
Kate McKinley | Chief Business Officer | USD 742.37K | 48 | 805.50K | 1.23% |
Talat Imran | Chief Executive Officer & Director | USD 549.93K | 44 | 461.81K | 0.71% |
Mir Hashim | Chief Scientific Officer | USD 416K | 66 | 325.00K | 0.50% |
Mir A. Imran | Executive Chairman | USD 30K | 70 | 2.12M | 3.24% |
Alireza Javadi | Chief Technical Officer | — | 42 | 9.07K | 0.01% |
Jesper Hoeiland | Head of Strategy | — | 66 | — | — |
Bella Vazquez | Senior Vice President of People & Administrative Services | — | — | — | — |
Arvinder Dhalla | Vice President of Clinical Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 27, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$50,033.00
Sells
1
$301.08
Net Transaction Value
+$49,731.92
Net buying
Most Active
IMRAN MIR A
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 21, 26Jul 21, 2026 | IMRAN MIR A Direct | Buy | $24.8K$24,840.00 |
| Jul 17, 26Jul 17, 2026 | Imran Talat Direct | Buy | $25.2K$25,193.00 |
| Mar 27, 26Mar 27, 2026 | Javadi Alireza Direct | Sell | $301.1$301.08 |
Summary
Insiders reported 2 buys worth $50,033.00 and 1 sells worth $301.08 over the last 12 months. That adds up to net buying of $49,731.92. IMRAN MIR A was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +94.7% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +94.7% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Rani Therapeutics Holdings, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about RANI's management, answered from reported figures.
Who manages RANI?
Rani Therapeutics Holdings, Inc. (RANI) lists 9 active executives. The top listed executive is Mir Hashim, Chief Scientific Officer.
Are RANI insiders buying or selling?
Recent insider activity shows net selling of $4.54M.
Continue the stock analysis
Jump to another research area for this company.